免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： av无码网址 | 天天干天天插 | 国产精品秘 麻豆果冻传媒下载 | 高清av无码 | 无码精品久久久 | 四季AV无码一区二区三区在线播放 | 亚洲精品无码一区二区三 | 小视频你懂的 | 欧美日韩成人网站 | 国产老师娇喘喷白浆在线播放 | 三级片免费看 | 特级西西444WWW大精品视频 | 国产精品国产成人国产三级 | 69仙踪林精品视频一区二区 | 成人无码区免费A∨直播网站 | 午夜精品久久久久久久久 | 国产精品白丝AV久久网站 | 懂色AV蜜臀av色欲av浪潮av | 激情小说综合网 | 精品人妻一区二区三区浪潮在线 | 五月深爱激情网 | 无码人妻丰满熟妇精品区东京直播 | 无码AV电影在线 | 7799精品视频天天综合在线观看 | 极品美女无套啪啪 | 亚洲AV成人无码一区二区在线 | 2025高清无码在线观看 | 69国产精品久久久久久人 | 亚洲成人AV在线观看 | 日本黄页 | 狠狠人妻久久久久久综合蜜桃 | 午夜精品一区二区三区有限公司 | 偷拍精品一区 | 无码免费阴 | 亚洲人成在线播放 | 无码精品一区二区三区在线观看 | 91在线视频观看 | 中文字幕日本有码 | 无码免费一区二区三区 | 精品久久久久久 | 国产一级内射 |